

# Tuberculosis (TB) Risk Assessment

Name: \_\_\_\_\_

The Center for Health and Counseling Services

Date of Birth: \_\_\_\_\_

Mother Teresa Hall  
(815)836-5455

Persons with any of the following are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented:

## Risk Factor

Recent close contact with someone with infectious TB disease	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Foreign-born from (or travel* to/in) a high-prevalence area (e.g., Africa, Asia, Eastern Europe, or Central or South America)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Fibrotic changes on a prior chest x-ray suggesting inactive or past TB disease	<input type="checkbox"/> Yes	<input type="checkbox"/> No
HIV/AIDS	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Organ transplant recipient	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Immunosuppressed (equivalent of > 15mg/day of prednisone for > 1 month or TNF- $\alpha$ antagonist)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
History of illicit drug use	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Resident, employee, or volunteer in a high risk congregate setting (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health care facilities)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Medical condition associated with increased risk of progressing to TB disease if infected [e.g., diabetes mellitus, silicosis, head, neck, or lung cancer, hematologic or reticuloendothelial disease such as Hodgkin's disease or leukemia, end stage renal disease, intestinal bypass or gastrectomy, chronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)].	<input type="checkbox"/> Yes	<input type="checkbox"/> No

\*The significance of the travel exposure should be discussed with a health care provider and evaluated.

**1. Does the student have signs or symptoms of active tuberculosis disease?** Yes \_\_\_ No \_\_\_

If No, proceed to 2 or 3. If Yes, proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

## 2. Tuberculin Skin Test (TST)-Two Step Testing REQUIRED

(TST result should be recorded as actual millimeters (mm) of palpable induration, transverse diameter; if no induration, write "0 mm". The TST interpretation should be based on mm of induration as well as risk factors.)\*\* TST results must be read and recorded by a trained health professional 48-72 hours after administration. Persons with a second TST(booster) response of 10mm or more should be considered to have experienced past or old infection.

**First Step**-Date Given: \_\_\_/\_\_\_/\_\_\_ Date Read: \_\_\_/\_\_\_/\_\_\_  
M D Y M D Y

Result: \_\_\_\_\_ mm of induration \*\*Interpretation: Positive \_\_\_ Negative \_\_\_

The second step should be performed 1-4 weeks after the first step

**Second Step**-Date Given: \_\_\_/\_\_\_/\_\_\_ Date Read: \_\_\_/\_\_\_/\_\_\_  
M D Y M D Y

Result: \_\_\_\_\_ mm of induration \*\*Interpretation: Positive \_\_\_ Negative \_\_\_

## Tuberculosis (TB) Risk Assessment

### 3. Interferon Gamma Release Assay (IGRA)

Date obtained: \_\_\_/\_\_\_/\_\_\_ (specify method) QFT-G QFT-GIT T-Spot  
Other \_\_\_\_\_ M D Y

Result: Negative \_\_\_ Positive \_\_\_ Indeterminate \_\_\_ Borderline \_\_\_ (T-Spot only)

Date obtained: \_\_\_/\_\_\_/\_\_\_ (specify method) QFT-G QFT-GIT T-Spot  
Other \_\_\_\_\_ M D Y

Result: Negative \_\_\_ Positive \_\_\_ Indeterminate \_\_\_ Borderline \_\_\_ (T-Spot only)

### 4. Chest x-ray (Required if TST or IGRA is positive)

Date of chest x-ray: \_\_\_/\_\_\_/\_\_\_ Result: Normal \_\_\_ Abnormal \_\_\_  
M D Y

#### \*\*Interpretation guidelines

>5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray consistent with past TB disease
- Organ transplant recipients
- Immunosuppressed persons: taking > 15mg/day of prednisone for > 1 month; taking a TNF- $\alpha$  antagonist
- Persons with HIV/AIDS

>10 mm is positive:

- Persons born in a high prevalence country or who resided in one for a significant\* amount of time
- History of illicit drug use
- Mycobacteriology laboratory personnel
- History of resident, worker or volunteer in high risk congregate settings
- Persons with the following clinical conditions: silicosis, diabetes mellitus, chronic renal failure, leukemias and lymphomas, head, neck, or lung cancer, low body weight (>10% below ideal), gastrectomy or intestinal bypass, chronic malabsorption syndromes

>15 mm is positive:

- Persons with no known risk factors for TB disease

\*The significance of the travel exposure should be discussed with a health care provider and evaluated.

---

Health Care Provider Printed Name or Stamp

---

Health Care Provider Address

Phone

---

Health Care Provider Signature

Date

Mail or fax completed form to: The Center for Health and Counseling Services at Lewis University  
One University Parkway (Unit #273)  
Romeoville, Illinois 60446

Fax: (815) 836-5047  
Phone: (815) 836-5455  
[www.lewisu.edu](http://www.lewisu.edu)